Circ_0001667 knockdown blocks cancer progression and attenuates adriamycin resistance by depleting NCOA3 via releasing miR-4458 in breast cancer.

Cui, Yanfei; Fan, Jing; Shi, Wenbo; Zhou, Zuozhi

Cui, Yanfei; Fan, Jing; Shi, Wenbo; Zhou, Zuozhi.

Afiliação

Cui Y; Department of Tumor Diagnosis and Treatment Center of Chinese and Western mtegrative Medicine, The Central Hospital of Enshi Tujia And Miao Autonomous Prefectrue, Enshi City, Hubei Province, China.
Fan J; Department of Tumor Diagnosis and Treatment Center of Chinese and Western mtegrative Medicine, The Central Hospital of Enshi Tujia And Miao Autonomous Prefectrue, Enshi City, Hubei Province, China.
Shi W; Department of Oncology, The Central Hospital of Enshi Tujia And Miao Autonomous Prefectrue, Enshi City, Hubei Province, China.
Zhou Z; Department of Tumor Diagnosis and Treatment Center of Chinese and Western mtegrative Medicine, The Central Hospital of Enshi Tujia And Miao Autonomous Prefectrue, Enshi City, Hubei Province, China.

Drug Dev Res ; 83(1): 75-87, 2022 02.

Article em En | MEDLINE | ID: mdl-34227151

Assuntos

Neoplasias da Mama; MicroRNAs; RNA Circular/genética; Animais; Neoplasias da Mama/tratamento farmacológico; Neoplasias da Mama/genética; Neoplasias da Mama/metabolismo; Proliferação de Células; Doxorrubicina/farmacologia; Feminino; Humanos; Camundongos; Camundongos Nus; MicroRNAs/metabolismo; Coativador 3 de Receptor Nuclear/genética; Coativador 3 de Receptor Nuclear/metabolismo

Palavras-chave

NCOA3; adriamycin; breast cancer; circ_0001667; miR-4458

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / MicroRNAs / RNA Circular Limite: Animals / Female / Humans Idioma: En Revista: Drug Dev Res Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google